2401867-58-9
Chemical Structure
JBJ-08-178-01
- CAS No.: 2401867-58-9
- Formula:C31H30N8O3
- Molecular Weight:562.62
InChIKey: XBWYQGMQBNVPMF-VOTSOKGWSA-N
SMILES: CC1=CC(NC2=C3C=C(NC(/C=C/CN(C)C)=O)C(OCC)=CC3=NC=C2C#N)=CC=C1OC4=CC5=NC=NN5C=C4
Biological Activity: JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JBJ-08-178-01 | JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Rubin E, et al. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers. Int J Mol Sci. 2024 Jan 15;25(2):1064. [Content Brief]
- [2]. Vathiotis IA, et al. Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond. Cancers (Basel). 2023 Feb 17;15(4):1286. [Content Brief]
- [3]. Son J, et al. A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer. Cancer Res. 2022 Apr 15;82(8):1633-1645. [Content Brief]
Keywords
